Purpose: To systematically analyze the overall m6A modification pattern in hyperplastic scars (HS).Methods: The m6A modification patterns in HS and normal skin (NS) tissues were described by m6A sequencing and RNA sequencing, and subsequently bioinformatics analysis was performed. The m6A-related RNA was immunoprecipitated and verified by real-time quantitative PCR.Results: The appearance of 14,791 new m6A peaks in the HS sample was accompanied by the disappearance of 7,835 peaks. The unique m6A-related genes in HS were thus associated with fibrosis-related pathways. We identified the differentially expressed mRNA transcripts in HS samples with hyper-methylated or hypo-methylated m6A peaks.Conclusion: This study is the first to map the m6A ...
Scars are maintained for life and increase in size during periods of growth such as puberty. Epigene...
We performed a database mining on 102 transcriptomic datasets for the expressions of 29 m6A-RNA meth...
AbstractUrokinase type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) hav...
The molecular mechanisms behind the pathogenesis of postburn hypertrophic scar (HS) remain unclear. ...
N6-Methyladenosine (m6A), a unique and common mRNA modification method in eukaryotes, is involved in...
The mechanisms of hypertrophic scar formation are not fully understood. We previously screened the d...
Homeostasis of the skin is achieved through tightly-regulated control of epidermal cell fate. Loss o...
Over 100 types of cellular RNA modifications have been identified in both coding and a variety of no...
Recent studies have revealed that the RNA N6-methyladenosine (m6A) modification plays a critical rol...
Purpose: The present study was carried out to investigate the global m6A-modified RNA pattern and po...
The clinical aspects of hypertrophic scarring vary according to personal constitution and body part....
Abstract Background Hypertrophic scar (HTS) is a fibrotic disorder of skins and may have repercussio...
Objective: The aim of this study was to examine the gene expression signatures of 2 types of excessi...
As the most common post-transcriptional RNA modification, m6A methylation extensively regulates the ...
N6-Methyladenosine (m6A) is the most widespread internal RNA modification in several species. In spi...
Scars are maintained for life and increase in size during periods of growth such as puberty. Epigene...
We performed a database mining on 102 transcriptomic datasets for the expressions of 29 m6A-RNA meth...
AbstractUrokinase type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) hav...
The molecular mechanisms behind the pathogenesis of postburn hypertrophic scar (HS) remain unclear. ...
N6-Methyladenosine (m6A), a unique and common mRNA modification method in eukaryotes, is involved in...
The mechanisms of hypertrophic scar formation are not fully understood. We previously screened the d...
Homeostasis of the skin is achieved through tightly-regulated control of epidermal cell fate. Loss o...
Over 100 types of cellular RNA modifications have been identified in both coding and a variety of no...
Recent studies have revealed that the RNA N6-methyladenosine (m6A) modification plays a critical rol...
Purpose: The present study was carried out to investigate the global m6A-modified RNA pattern and po...
The clinical aspects of hypertrophic scarring vary according to personal constitution and body part....
Abstract Background Hypertrophic scar (HTS) is a fibrotic disorder of skins and may have repercussio...
Objective: The aim of this study was to examine the gene expression signatures of 2 types of excessi...
As the most common post-transcriptional RNA modification, m6A methylation extensively regulates the ...
N6-Methyladenosine (m6A) is the most widespread internal RNA modification in several species. In spi...
Scars are maintained for life and increase in size during periods of growth such as puberty. Epigene...
We performed a database mining on 102 transcriptomic datasets for the expressions of 29 m6A-RNA meth...
AbstractUrokinase type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) hav...